
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES92
The extension phase of the HOPE study showed a NS trend towards reduction in major CV
events and risk of MI, with ramipril, stroke and CV death as NS. At follow-up of the study and
extension there was a significant risk reduction with ramipril for the outcomes of MI, stroke
and CV death.241 Level 1+

[@Casas_2005]

